New heart risks associated with fluoroquinolone antibiotics

19 September 2019

2019_vials_production_manufacturing_biotech_big

New research examining the impact of antibiotics suggests that fluoroquinolones could create an elevated risk of developing aortic and mitral regurgitation, serious heart problems.

Published in the Journal of the American College of Cardiology, the study compared 12,505 cases of valvular regurgitation with 125,020 control participants, using the US Food and Drug Administration’s adverse reporting system database and a large private insurance health claims database.

People using fluoroquinolones such as ciprofloxacin had a 2.4 times greater risk of developing the conditions, compared with those using amoxicillin or azithromycin.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK